These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26878155)

  • 21. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
    Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
    World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice.
    Razenberg LG; van Gestel YR; de Hingh IH; Loosveld OJ; Vreugdenhil G; Beerepoot LV; Creemers GJ; Lemmens VE
    BMC Cancer; 2016 Feb; 16():110. PubMed ID: 26882902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer.
    Khattak MA; Townsend AR; Beeke C; Karapetis CS; Luke C; Padbury R; Maddern G; Roder D; Price TJ
    Eur J Cancer; 2012 Jun; 48(9):1293-8. PubMed ID: 22119202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.
    Kiss I; Bortlicek Z; Melichar B; Poprach A; Halamkova J; Vyzula R; Dusek L; Buchler T
    Anticancer Res; 2014 Feb; 34(2):949-54. PubMed ID: 24511038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
    Yang H; Yu AP; Wu EQ; Yim YM; Yu E
    J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of bevacizumab on survival outcomes in primary tumor resected metastatic colorectal cancer.
    Kodaz H; Erdogan B; Hacibekiroglu I; Turkmen E; Gurkan H; Albayrak D; Tastekin E; Uzunoglu S; Cicin I
    Med Oncol; 2015 Jan; 32(1):441. PubMed ID: 25502088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer.
    Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ueno M; Yamaguchi T
    Asia Pac J Clin Oncol; 2014 Dec; 10(4):322-9. PubMed ID: 23915091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.
    Grothey A; Flick ED; Cohn AL; Bekaii-Saab TS; Bendell JC; Kozloff M; Roach N; Mun Y; Fish S; Hurwitz HI
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):726-34. PubMed ID: 24830357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The predictive and prognostic value of the Glasgow Prognostic Score in metastatic colorectal carcinoma patients receiving bevacizumab.
    Maillet M; Dréanic J; Dhooge M; Mir O; Brezault C; Goldwasser F; Chaussade S; Coriat R
    Anticancer Drugs; 2014 Nov; 25(10):1215-9. PubMed ID: 24858536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
    Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
    Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
    Hecht JR; Mitchell E; Chidiac T; Scroggin C; Hagenstad C; Spigel D; Marshall J; Cohn A; McCollum D; Stella P; Deeter R; Shahin S; Amado RG
    J Clin Oncol; 2009 Feb; 27(5):672-80. PubMed ID: 19114685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.
    Giantonio BJ
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S15-8. PubMed ID: 17145520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis.
    Cao D; Zheng Y; Xu H; Ge W; Xu X
    Sci Rep; 2019 Dec; 9(1):20326. PubMed ID: 31889159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
    Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
    Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.